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the risk of HF hospitalization and mortality.1 
However, most HF patients included in clinical 
trials with β ‑blockers were in sinus rhythm, with 
only 11% to 35% of patients with atrial fibrilla‑
tion (AF).2-5 Moreover, a recent meta ‑analysis of 
10 randomized controlled trials, including pa‑
tients with HFrEF, has shown no improvement in 
INTRODUCTION According to the current guide‑
lines, β ‑blockers are recommended in addition 
to angiotensin ‑converting enzyme inhibitors 
as the first ‑line therapy for patients with sta‑
ble and symptomatic heart failure (HF) with re‑
duced ejection fraction (HFrEF).1 In that pop‑
ulation, β ‑blockers have been proved to reduce 
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ABSTRACT
INTRODUCTION The positive effect of β ‑blocker therapy in patients with heart failure (HF) and atrial 
fibrillation (AF) has been questioned.
OBJECTIVES We aimed to assess the effect of β ‑blockers and heart rate (HR) control on 1 ‑year outcomes 
in patients with HF and AF.
PATIENTS AND METHODS Of the 2019 Polish patients enrolled in ESC ‑HF Pilot and ESC ‑HF Long ‑Term 
Registry, 797 patients with HF and AF were classified into 2 groups depending on β ‑blocker use. Ad‑
ditionally, patient survival was compared between 3 groups classified according to HR: lower than 
80 bpm, between 80 and 109 bpm, and of 110 bpm or higher. The primary endpoint was all ‑cause death 
and the secondary endpoint was all ‑cause death or HF hospitalization.
RESULTS In patients treated with β ‑blockers, the primary and secondary endpoints were less frequent 
than in patients not using β ‑blockers (10.9% vs 25.6%, P = 0.001 and 30.6% vs 44.2%, P = 0.02, re‑
spectively). Absence of β ‑blocker treatment was a predictor of both endpoints in a univariate analysis 
but remained an independent predictor only of the primary endpoint in a multivariate analysis (hazard 
ratio for β ‑blocker use, 0.52; 95% CI, 0.31–0.89; P = 0.02). The primary and secondary endpoints were 
more frequent in patients with a HR of 110 bpm or higher, but the HR itself did not predict the study 
endpoints in the univariate analysis.
CONCLUSIONS β ‑blocker use might decrease mortality in patients with HF and AF, but it seems to have 
no impact on the risk of HF hospitalization. An HR of 110 bpm or higher may be related to worse survival 
in these patients.
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ECG. The study included patients with all types of 
AF (ie, paroxysmal, persistent, and permanent). 
The exclusion criteria were as follows: death dur‑
ing baseline hospitalization (in the case of hospi‑
talized patients; n = 42), lack of data on β ‑blocker 
prescription (n = 3), and lack of ECG documenta‑
tion on the leading heart rhythm or presence of 
rhythm other than AF (n = 1177).
Of the 2019 Polish patients with HF (including 
ambulatory patients and patients discharged after 
hospitalization for HF), 797 individuals (39.5%) 
with AF were selected and included in the pres‑
ent study. Patients were classified into 2 groups 
depending on β ‑blocker use and were followed 
for 1 year. The population included 445 patients 
(56%) with a left ventricular ejection fraction 
(LVEF) of 40% or lower and 300 patients (38%) 
with a LVEF higher than 40% (LVEF data were 
missing in 52 patients [6%]). Data on 1 ‑year 
survival were available for 763 patients (96.2%), 
and on hospitalization for decompensated HF 
at 1 ‑year follow ‑up, for 711 of the 797 patients 
(89.2%).
Clinical endpoints and design of analyses Patients 
treated with β ‑blockers were compared with those 
not receiving β ‑blockers in terms of baseline 
characteristics and 1 ‑year outcomes. The prima‑
ry endpoint was all ‑cause death at 1 year, while 
the secondary endpoint was a composite of all‑
‑cause death and hospitalization for worsening 
HF at 1 year. We also sought to determine whether 
β ‑blocker treatment was an independent predic‑
tor of both endpoints in the study cohort.
An additional analysis was performed to as‑
sess the relationship between baseline resting HR 
and 1 ‑year outcomes in the study population. Pa‑
tients were divided into 3 subgroups depending 
on baseline resting HR (791 of the 797 patients 
with known resting HR): 464 patients (58.7%) 
with an HR below 80 bpm; 297 patients (37.5%) 
with an HR between 80 and 109 bpm; 30 patients 
(3.8%) with an HR of 110 bpm or higher. We chose 
the cutoff value of 110 bpm according to the lat‑
est 2016 ESC guidelines,10 and the cutoff value 
of 80 bpm as adopted in the previous 2010 ESC 
guidelines and the RACE II study.14,15
Statistical analysis For a between ‑group compar‑
ison, we used the Fisher exact test and the Mann– 
–Whitney test for categorical and continuous 
variables, respectively. Categorical data were pre‑
sented as the number and percentage of patients. 
Normally distributed continuous variables were 
presented as a mean value with SD. For ordinal 
variables and nonnormally distributed continu‑
ous variables, a median value with interquartile 
range (IQR) was used. To identify predictors of 
the primary and secondary endpoints, we per‑
formed the Cox proportional hazards regression 
model. Variables found to be significant in uni‑
variate analyses were included in multivariate 
models. The Kaplan–Meier curves were plotted 
for the 2 primary subgroups (with and without 
long ‑term prognosis on β ‑blocker therapy in pa‑
tients with HF and AF.6 Moreover, it has shown 
no benefit of β ‑blocker treatment in any of the AF 
subgroups (selected based on age, sex, left ven‑
tricular ejection fraction, New York Heart Asso‑
ciation [NYHA] class, heart rate [HR], and base‑
line medical therapy).6 In contrast, a large nation‑
wide Swedish registry7 and a post hoc analysis of 
the AF ‑CHF trial8 (Atrial Fibrillation ‑Congestive 
Heart Failure) showed a significant reduction of 
all ‑cause mortality in patients with HF and AF 
treated with β ‑blockers (a relative risk reduction 
of 25% and 28%, respectively).
Another important consideration in HF pa‑
tients with permanent AF is the optimal resting 
HR, which is still uncertain. It was observed that 
ventricular rates under 70 bpm may be associ‑
ated with worse outcomes in patients with HF 
and AF.9 The current European Society of Cardi‑
ology (ESC) guidelines on HF management sug‑
gest a threshold of 60 to 100 bpm, while the ESC 
guidelines on AF propose a less strict threshold 
of less than 110 bpm (and avoiding bradycar‑
dia), as a target for rate control therapy in this 
population.1,10
The aim of this study was to investigate the ef‑
fect of β ‑blockers on 1 ‑year outcomes in real ‑life 
patients with HF and concomitant AF. An ad‑
ditional analysis was designed to assess the re‑
lationship between HR control and 1 ‑year out‑
comes in these patients.
PATIENTS AND METHODS Study design This co‑
hort study was based on data from 2 prospective 
observational ESC registries: ESC ‑HF Pilot and 
ESC ‑HF Long ‑Term. The current analysis includ‑
ed data collected in Polish cardiology centers. De‑
tailed information on the design of both registries 
was published previously.11-13 Both surveys were 
approved by a local institutional review board and 
all patients signed informed consent to partici‑
pate in the registries.
Study population and group selection The ESC ‑HF 
Pilot and Long ‑Term registries enrolled 5118 and 
12 440 patients with HF, respectively, across Eu‑
rope. The current analysis comprised 2019 white 
Polish patients including those who were dis‑
charged in stable condition following HF hospi‑
talization (n = 1415) and ambulatory HF patients 
(n = 604). Both HF registries collected the same 
type of clinical data.
The  main analysis was designed to assess 
clinical characteristics and 1 ‑year prognosis of 
HF patients with concomitant AF treated with 
β ‑blockers in comparison with patients with HF 
and AF who did not receive β ‑blockers. Patients 
were eligible for inclusion in the study if they had 
a diagnosis of AF based on a 12 ‑lead electrocar‑
diogram (ECG) or Holter monitoring performed 
during baseline visit or earlier. A case report form 
enabled the investigators to choose only one lead‑
ing heart rhythm for each patient (sinus rhythm, 
AF, paced rhythm, or other) based on a 12 ‑lead 
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Heart rate control Heart rate, assessed as a con‑
tinuous variable, was not a predictor of either 
the primary or the secondary endpoint in the to‑
tal population, even in the univariate analysis. 
However, the Kaplan–Meier curves (FIGURES 3  and 4) 
showed increased rates of the primary and sec‑
ondary endpoints in patients with an HR of 
110 bpm or higher. Both study endpoints were 
less frequent in patients with an HR of 80 to 
109 bpm when compared with the remaining HR 
subgroups. However, significance was reached 
only for the  secondary endpoint (27.5% vs 
35.0%; P = 0.046) and not for the primary one 
(9.9% vs 14.2%; P = 0.09) (FIGURE 5).
DISCUSSION The results of this study may sup‑
port current recommendations to prescribe 
β ‑blockers in patients with HF, irrespective of 
the simultaneous presence of AF. In our popula‑
tion, β ‑blocker use was an independent prognos‑
tic factor in the 1 ‑year follow ‑up. The most favor‑
able 1 ‑year prognosis was observed in patients 
with a resting HR of 80 to 109 bpm.
Patients with AF constitute a specific subgroup 
within the HF population, and AF is a highly prev‑
alent condition in patients with HF.1,16 Its preva‑
lence increases with the severity of HF, from 10% 
in NYHA functional class I to 50% in class IV.16,17 
The presence of AF in patients with HF is associ‑
ated with increased severity of symptoms, high 
risk of thromboembolic events, and worse long‑
‑term prognosis.18-20 AF patients are more likely 
β ‑blocker treatment), as well as for the 3 sub‑
groups divided according to HR. All tests were 
2 ‑tailed. A P value of less than 0.05 was con‑
sidered significant. The  SPSS software, ver‑
sion 22 (IBM SPSS Statistics 22, New York, Unit‑
ed States) was used for analysis.
RESULTS Baseline characteristics The mean (SD) 
age of the overall population was 68.0 (12.0) years 
and the mean (SD) resting HR was 80.2 (18.6) 
bpm. At baseline, 715 patients (89.7%) received 
β ‑blockers, while 82 patients (10.3%) were not 
treated with a β ‑blocker. Detailed comparative 
characteristics of both groups are presented in 
TABLES 1 and 2.
One -year outcomes Patients treated with β ‑blockers 
were less likely to reach the primary and second‑
ary endpoints than those not receiving β ‑blockers 
(10.9% vs 25.6%, P = 0.001 and 30.6% vs 44.2%, 
P = 0.02, respectively). The Kaplan–Meier curves 
for the primary and secondary endpoints for 
both subgroups are shown in FIGURES 1 and 2, 
respectively.
In the univariate analysis, β ‑blocker use in pa‑
tients with HF and AF was a predictor of both 
the primary and secondary endpoints. In the mul‑
tivariate analysis, β ‑blocker use remained an inde‑
pendent predictor of the primary endpoint (haz‑
ard ratio, 0.52; 95% CI, 0.31–0.89; P = 0.02) but 
not of the secondary endpoint (hazard ratio, 0.74; 
95% CI, 0.49–1.11; P = 0.14) (TABLE 3).
TABLE 1 Baseline characteristics (demographic data, heart failure, and medical history) of patients with heart failure and atrial fibrillation depending 
on β ‑blocker use
Parameter Total population 
(n = 797)
β ‑blocker treatment 
(n = 715)
No β ‑blocker treatment 
(n = 82)
P value
Demographic data
Age, y, median (IQR) 69.2 (60.6–78.0); n = 797 68.9 (60.1–77.3); n = 715 75.0 (65.5–80.9); n = 82 0.002
Male sex, % (n/N) 66.4 (529/797) 67.6 (483/715) 56.1 (46/82) 0.048
BMI, kg/m2, median (IQR) 28.1 (25.0–31.4); n = 771 28.0 (25.0–31.2); n = 694 28.4 (25.0–32.3); n = 77 0.7
Heart failure
LVEF, %, median (IQR) 38 (27.5–50); n = 745 37 (27–50); n = 667 45 (35–54); n = 78 0.001
Ischemic etiology, % (n/N) 45.3 (361/797) 44.5 (318/715) 52.4 (43/82) 0.2
Dilated cardiomyopathy, % (n/N) 18.2 (145/797) 19.4 (139/715 7.3 (6/82) 0.01
Patients discharged after HF 
hospitalization, % (n/N)
70.1 (561/797) 69.0 (493/715 82.9 (68/82) 0.01
Medical history, % (n/N)
Hypertension 65.7 (522/795) 65.4 (466/713 68.3 (56/82) 0.6
Coronary artery disease 47.3 (377/797) 45.6 (326/715) 62.2 (51/82) 0.01
Prior PCI or CABG 30.5 (243/797) 32.0 (229/715) 17.1 (14/82) 0.01
Peripheral artery disease 12.4 (99/796) 11.8 (84/714) 18.3 (15/82) 0.1
Diabetes 33.0 (263/797) 32.3 (231/715) 39.0 (32/82) 0.2
CKD 20.4 (162/796) 19.9 (142/714) 24.4 (20/82) 0.4
COPD 17.4 (139/797) 15.9 (114/715) 30.5 (25/82) 0.002
Stroke 13.8 (110/796) 13.9 (99/714) 13.4 (11/82) 1.00
Current smoking 51.5 (404/785) 52.6 (370/704) 42.0 (34/81) 0.08
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary 
disease; HF, heart failure; IQR, interquartile range; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention
POLISH ARCHIVES OF INTERNAL MEDICINE 2018; 128 (11)652
HF and concomitant COPD did not differ com‑
pared with patients without COPD.23 According 
to the current guidelines, β ‑blockers are not con‑
traindicated in patients with HF and COPD, al‑
though more selective β1‑antagonists (such as 
bisoprolol, metoprolol succinate, or nebivolol) 
are preferred.1
In our study, patients who did not receive 
β ‑blockers had a higher mean LVEF value (45%), 
thus most patients had HF with preserved LVEF 
(HFpEF) or HF with mid ‑range LVEF (HFmrEF). 
This might explain why those patients did not re‑
ceive β ‑blockers, as so far there has been no evi‑
dence of survival benefit of this therapy in HFpEF 
and HFmrEF.1 Still, in these patients, β ‑blockers 
should be considered for rate control.1 Recent 
data from the QUALIFY study (QUality of Ad‑
herence to guideline recommendations for LIFe‑
‑saving treatment in heart failure surveY) showed 
that most patients with HFrEF in Poland receive 
adequate treatment (including β ‑blockers), but 
the proportion of patients reaching the target 
to require a more intensive symptomatic treat‑
ment with the use of loop diuretics and miner‑
alocorticoid receptor antagonists than patients 
in sinus rhythm.18 Coexistence of HF and AF is 
associated with an increased risk of HF hospital‑
izations and mortality.19,21
In our analysis, patients who received and who 
did not receive β ‑blockers did not differ in se‑
verity of HF symptoms. Patients who did not re‑
ceive β ‑blockers were older, more often were fe‑
male, and more frequently had chronic obstruc‑
tive pulmonary disease (COPD), which might have 
affected underprescription of these medications. 
Patients with coexisting COPD are at high risk 
of adverse reactions associated with β ‑blocker 
use. However, Andell et al,22 based on data from 
a large Swedish registry (SWEDEHEART), found 
that COPD patients with a history of HF and after 
myocardial infarction treated with β ‑blockers had 
a significantly lower all ‑cause mortality. More‑
over, a previous analysis from the ESC ‑HF Pilot 
registry showed that mortality in patients with 
TABLE 2 Baseline characteristics (clinical status, laboratory findings, pharmacotherapy and implantable devices) and 1 ‑year outcomes of patients 
with heart failure and atrial fibrillation depending on β ‑blocker use
Variable Total  
(n = 797)
β ‑Blocker treatment 
(n = 715)
No β ‑blocker treatment 
(n = 82)
P value
Clinical status at baseline, median (IQR)
NYHA class 2 (2–3); n = 777 2 (2–3); n = 696 2 (2–3); n = 81 0.8
SBP, mmHg 120 (110–130); n = 796 120 (110–130); n = 714 120 (110–130); n = 82 0.3
DBP, mmHg 70 (70–80); n = 795 70 (70–80); n = 713 70 (68–80); n = 82 0.2
Heart rate, bpm 75 (68–83); n = 791 75 (70–83); n = 709 70 (65–80); n = 82 0.06
Laboratory findings at baseline, median (IQR)
Serum sodium, mmol/l 139.0 (136.0–141.0); n = 745 139.0 (136.2–141.0); n = 490 139.0 (136.0–141.0); n = 66 0.9
Serum potassium, mmol/l 4.4 (4.1–4.8); n = 749 4.4 (4.1–4.7); n = 498 4.5 (4.0–4.9); n = 67 0.4
Serum creatinine, mg/dl 1.10 (0.92–1.37); n = 746 1.10 (0.90–1.38); n = 456 1.06 (0.90–1.52); n = 60 0.8
Hemoglobin, g/dl 13.5 (12.1–14.7); n = 730 13.2 (11.9–14.6); n = 369 12.1 (11.0–13.5); n = 51 0.002
Pharmacotherapy and implantable devices, % (n/N)
ACEIs 75.6 (602/796) 76.5 (547/715) 67.9 (55/81) 0.1
ARBs 10.9 (87/796) 10.5 (75/715) 14.8 (12/81) 0.3
MRAs 70.4 (560/796) 72.7 (520/715) 49.4 (40/81) <0.001
Diuretics 86.7 (690/796) 87.4 (625/715) 80.2 (65/81) 0.08
Amiodarone 11.3 (90/796) 11.6 (83/715) 8.6 (7/81) 0.6
Other antiarrhythmic drugs 6.8 (54/796) 6.9 (49/715) 6.2 (5/81) 1.00
Statins 59.7 (475/796) 62.0 (443/715) 39.5 (32/81) <0.001
Anticoagulants 74.0 (589/796) 75.4 (539/715) 61.7 (50/81) 0.01
Antiplatelets 41.1 (327/796) 42.2 (302/715) 30.9 (25/81) 0.06
Digoxin 36.9 (294/796) 36.2 (259/715) 43.2 (35/81) 0.2
ICD 16.3 (130/797) 17.3 (124/715) 7.3 (6/82) 0.02
CRT 4.9 (39/797) 5.3 (38/715) 1.2 (1/82) 0.1
One ‑year outcome
Death 12.5 (95/763) 10.9 (74/681) 25.6 (21/82) 0.001
Death or rehospitalization 32.1 (228/711) 30.6 (194/634) 44.2 (34/77) 0.02
SI conversion factors: to convert hemoglobin to g/l, multiply by 0.6206; creatinine to μmol/l, by 0.00884.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; DBP, 
diastolic blood pressure; ICD, implantable cardioverter–defibrillator; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; 
SBP, systolic blood pressure; others, see TABLE 1
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including oral anticoagulation (OAC). Of note, as 
all AF patients in our study had a diagnosis of 
HF, all had at least 1 point in the CHA2DS2 ‑VASc 
score (congestive heart failure, hypertension, age 
>75 years, diabetes mellitus, history of stroke or 
thromboembolism, vascular disease, age 65 to 
74 years, female sex) and therefore at least class 
IIa indication for OAC.10 However, only 75.4% of 
participants on β ‑blockers and 61.7% of those not 
doses is suboptimal.23 Nevertheless, it seems 
that β ‑blocker prescription in the study group 
might have been also, at least in part, motivated 
by a resting HR: patients who received β ‑blockers 
had higher baseline HR compared with those 
who were not prescribed β ‑blockers (75 bpm vs 
70 bpm, P = 0.06).
Patients treated with β ‑blockers were also more 
likely to receive other evidence ‑based medications, 
FIGURE 1  
Kaplan–Meier curves for 
the primary endpoint in 
patients with heart failure 
and concomitant atrial 
fibrillation treated and not 
treated with β ‑blockers
FIGURE 2  
Kaplan–Meier curves for 
the secondary endpoint in 
patients with heart failure 
and concomitant atrial 
fibrillation treated and not 
treated with β ‑blockers
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treated with β ‑blockers had a 25% reduction in 
all ‑cause mortality in comparison with those who 
did not receive β ‑blockers.7 Similarly, in the oth‑
er study, β ‑blockers were associated with a sig‑
nificant 29% reduction in mortality.25 The anal‑
ysis was based on the Swedish Heart Failure Reg‑
istry and comprised 7392 HFrEF patients with 
concomitant AF.25 In a recent post hoc analysis 
of the AF ‑CHF trial, β ‑blockers were associated 
with a significant 28% reduction in all ‑cause mor‑
tality during a median follow ‑up of 37 months.8 
Similarly to our study, the AF ‑CHF trial showed 
a trend towards the association of β ‑blocker use 
with a reduced hospitalization rate, but the re‑
sult was not significant.8 It remains unclear why 
β ‑blockers have no favorable effect on the reduc‑
tion of hospital readmissions in patients with HF 
and AF. One possible explanation might be that 
these patients are frequently more symptomatic 
than HF patients in sinus rhythm, which may re‑
duce the beneficial effect of β ‑blockers.
The findings of the above analyses are in con‑
trast to the results of a recent meta ‑analysis 
that included data from 10 randomized trials of 
β ‑blockers versus placebo in patients with HFrEF.6 
The meta ‑analysis indicated that, in contrast to 
HF patients with sinus rhythm, β ‑blockers do not 
improve prognosis in HF patients with AF (hazard 
ratio, 0.97; P = 0.73).6 The authors recommend‑
ed against β ‑blocker use in patients with HF and 
AF.6 Similar results were observed in a smaller 
meta ‑analysis including 4 randomized placebo‑
‑controlled trials, which enrolled 1677 patients 
with HF and AF.26 Rienstra et al26 suggested that 
in these patients β ‑blockers did not reduce mor‑
tality (odds ratio [OR], 0.86; 95% CI, 0.66–1.13; 
P = 0.28) and hospitalizations (OR, 1.11; 95% CI, 
0.85–1.47; P = 0.44), in contrast to patients in si‑
nus rhythm. However, both meta ‑analyses gener‑
ated some controversies. The first meta ‑analysis 
included patients with advanced disease, high‑
ly symptomatic (70% had NYHA class III or IV), 
with a high proportion of digoxin use and OAC 
underuse (only 58% of patients), which might 
have reduced the benefit of β ‑blocker therapy.6 
In the meta ‑analysis by Rienstra et al,26 the ac‑
tual prevalence of AF might have been low (pa‑
tients were included in the study based only on 
one ECG). However, in the AF ‑CHF trial, the as‑
sociation of β ‑blocker use and outcomes was con‑
sistent regardless of AF type (persistent or par‑
oxysmal) and its duration.8 Despite these con‑
troversies, the 2016 ESC guidelines on HF main‑
tained the recommendation of β ‑blocker use in 
patients with HF and AF.1
Higher HR in HF patients was proved to be as‑
sociated with higher long ‑term mortality.27,28 In 
our previous study, HR at hospital discharge was 
a predictor of 1 ‑year death in HF patients, both 
those with AF and those in sinus rhythm.18 How‑
ever, based on the results of the MAGGIC meta‑
‑analysis conducted in HF patients, resting HR 
does not have the same prognostic implications 
in patients with AF as it does in those in sinus 
on β ‑blockers (P = 0.01) received OAC. The un‑
derprescription of OAC, especially in the non–β ‑
‑blocker subgroup, might be partly explained by 
older age and lower hemoglobin levels. However, 
it was shown that elderly patients with AF rare‑
ly have absolute contraindications to OAC and it 
is therefore underused.24
In our study, patients not treated with β ‑blockers 
were significantly more likely to reach the pri‑
mary and secondary endpoints than patients re‑
ceiving β ‑blockers. In the multivariate analysis, 
β ‑blocker use was proved to be an independent 
positive predictor of 1 ‑year survival, but not of 
the composite endpoint of death and hospital re‑
admissions. It should be stressed that, because of 
a small group of patients who were not treated 
with β ‑blockers, our analysis was performed re‑
gardless of LVEF, which might have biased the re‑
sults. However, our findings are in line with data 
from 2 large registries with a similar methodolo‑
gy.7,25 The first one was a propensity ‑matched co‑
hort from a Danish nationwide registry, including 
23 896 AF patients with concomitant HF (both 
HFrEF and HFpEF).7 It revealed that patients 
TABLE 3 Predictors of the primary and secondary endpoints at 1 ‑year in patients 
with heart failure and atrial fibrillation in a multivariate analysis
Variable Primary endpoint Secondary endpoint
HR (95% CI) P value HR (95% CI) P value
Demographic data
Age, per 10 years 1.02 (1.10–1.63) 0.06 0.98 (0.95–1.34) 1.01
Heart failure
LVEF, per 5% – – 1.32 (0.98–1.01) 0.1
Medical history
CAD 1.17 (0.75–1.84) 0.5 1.09 (0.80–1.50) 0.6
Diabetes – – 1.52 (1.12–2.05) 0.007
COPD 2.29 (1.45–3.63) <0.001 1.39 (0.98–1.95) 0.06
CKD 1.53 (0.95–2.47) 0.08 1.32 (0.95–1.92) 0.09
Laboratory findings
Hemoglobin, per 
1 g/dl
0.97 (0.86–1.09) 0.6 0.94 (0.87–1.02) 0.1
Serum sodium, per 
1 mmol/l
0.95 (0.91–0.99) 0.03 0.98 (0.95–1.01) 0.3
Clinical status
NYHA class, per 
1 class
0.98 (0.69–1.38) 0.9 1.17 (0.93–1.50) 0.2
SBP, per 10 mmHg 0.82 (0.74–0.90) 0.01 0.99 (0.98–1.01) 0.2
Hospitalization 
statusa
3.33 (1.32–8.41) 0.01 2.87 (1.72–4.78) <0.001
Pharmacotherapy
Diuretics – – 1.32 (0.77–2.29) 0.3
β ‑blockers 0.52 (0.31–0.89) 0.02 0.76 (0.51–1.15) 0.2
a On enrollment
The table includes only variables that were significant predictors of either the primary 
or secondary endpoint in univariate analyses. Variables found to be predictors of 
the study endpoints in univariate analyses were subsequently included in multivariate 
analyses.
Abbreviations: CAD, coronary artery disease; HR, hazard ratio; others see TABLES 1 and 2
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that because of the small size of the total popula‑
tion, there were only few events in each subgroup.
According to the guidelines, β ‑blockers are 
the first ‑line drugs to control ventricular rate in 
patients with HF and AF.1 However, the optimal 
resting HR remains uncertain, as previous stud‑
ies (AFFIRM, RACE) showed no difference in clin‑
ical events in the strict rate ‑control groups versus 
lenient rate ‑control groups.14,30 The current ESC 
rhythm.29 In our study, patients with HF and AF 
with an HR of 110 bpm or higher had a higher risk 
of death in 1 ‑year follow ‑up than patients with 
an HR in the range of 80 to 109 bpm. Moreover, 
the risk of death or hospitalization for HF wors‑
ening was observed less frequently in patients 
with an HR of 80 to 109 bpm when compared 
with patients with an HR of 110 bpm or higher or 
less than 80 bpm. However, it should be stressed 
FIGURE 3  
Kaplan–Meier curves for 
the primary endpoint in 
patients with heart failure 
and concomitant atrial 
fibrillation depending on 
heart rate
FIGURE 4  
Kaplan–Meier curves for 
the secondary endpoint in 
patients with heart failure 
and concomitant atrial 
fibrillation depending on 
heart rate
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patients with all types of AF (paroxysmal, per‑
sistent, and permanent) as a single study group. 
The most appropriate approach would probably be 
to evaluate patients with permanent AF and those 
with paroxysmal AF separately. However, this 
would increase the complexity of the study and 
further reduce the size of the study subgroups, 
thus precluding any reliable analysis.
An important advantage of registries is inclu‑
sion of real ‑life patients, but drawbacks include 
partial incompleteness of the data, as shown in 
TABLES 1 and 2. The findings of our study corre‑
spond with previously published data from large 
registries,7,19,25,32 but randomized clinical trials 
are needed to clarify the effect of β ‑blockers on 
long ‑term outcomes in HF patients with con‑
comitant AF.
Conclusions In patients with HF and AF treat‑
ed with β ‑blockers, we observed lower mortali‑
ty rates at 1 year in comparison with those not 
receiving β ‑blockers. In these patients, an HR of 
80 bpm to 109 bpm may be associated with better 
outcomes, while patients with an HR of 110 bpm 
or higher have worse survival. However, β ‑blocker 
treatment seemed to have no impact on the risk 
of hospitalization for HF worsening in patients 
with HF and AF. These data indicate the need for 
further properly designed comparative studies to 
confirm the possible benefits of β ‑blocker treat‑
ment, as well as to establish a target resting HR 
value in this patient population.
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guidelines on HF suggest that the optimal HR 
for patients with HF and AF might be between 
60 bpm and 100 bpm,1 while the ESC guidelines 
on AF accept a resting ventricular rate of up to 
110 bpm and recommend avoiding bradycardia.10 
In an analysis of data from the EORP ‑AF Pilot reg‑
istry (EURObservational Research Programme‑
‑Atrial Fibrillation General Registry Pilot Phase), 
Lenarczyk et al31 showed that a rhythm ‑control 
strategy is used more frequently in Poland than 
in other European countries. A recent analysis of 
the CIBIS II trial showed that in HFrEF patients 
with AF, in contrast to HFrEF patients in sinus 
rhythm, higher HR was not associated with worse 
outcomes.3 Similarly, in the Swedish Heart Fail‑
ure Registry, mortality was increased with high‑
er HR in sinus rhythm, while in AF, mortality was 
increased only for an HR higher than 100 bpm.25
Limitations of the study The main limitation of 
our study is a relatively low number of patients, 
especially in the control group (ie, patients not 
receiving β ‑blockers) and in the subgroup of pa‑
tients with an HR of 110 bpm or higher. Thus, 
the reporting of findings for the HR subgroups 
may be underpowered. Due to relatively small 
groups, we were not able to assess the effect of 
β ‑blockers with respect to LVEF or to conduct 
a propensity score matching analysis.
Another important limitation of our study is 
a joint analysis of ambulatory HF patients and 
HF patients discharged after HF hospitalization. 
We decided to combine these 2 subgroups to in‑
crease the number of study patients and thus 
the statistical power of the analysis. The propor‑
tion of patients discharged after HF hospitaliza‑
tion was significantly higher in the group not 
treated with β ‑blockers. Still, in the multivariate 
analysis, β ‑blocker treatment remained a signifi‑
cant predictor of the primary endpoint irrespec‑
tive of the recent hospitalization.
Due to a relatively small number of patients, 
we decided to perform a combined analysis of 
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